Advanced Aortic Disease
A comprehensive care model, uniquely designed by a team of specialists, drives innovation and better outcomes for complex aortic disease.
Elevating care
2024 Outcomes
Overview
Our aortic team includes geneticists, interventional cardiologists, vascular surgeons, radiologists and cardiothoracic surgeons. We provide advanced treatment options, including minimally invasive repairs, endovascular grafts, robotic surgery and hybrid surgical approaches for the aortic root, thoracic aorta, abdominal aorta and complex aortic valve repairs.
Accomplishments
- Plano has seen a two-year growth of 106% with the resurgence of the Ross procedure. Being the only aortic valve replacement demonstrated to restore life expectancy to normal, we are leading the way in increasing access to the Ross procedure. During this time, Plano has experienced 0% stroke, re-operation for valve dysfunction, post-operative aortic re-intervention and renal failure.
- With cutting-edge technology and skilled surgeons, Plano has achieved a rate of 0% with CVA, re-intervention, spinal ischemia and MI posturgent thoracic endovascular aortic repairs. Additionally, the post-operative length of stay for this population has been reduced to just 3.8 days, a 56% reduction from the previous year.
- With the growth of valve-sparing aortic root surgeries, Plano has experienced a 0% mortality rate over the last three years.
- Within the acute Type A dissection population—the highest risk cohort—we achieved a 0% stroke rate and 16% 30-day mortality rate, both superior to national benchmarks.
- Thoracic aortic aneurysm repair performed electively achieved a 0.9% stroke rate and 0.4% mortality rate, again accomplishing better than national benchmarks.
thoracic aortic procedures (plano)
172
ROOT
100
ARCH
273
ASC
76
DESC/TAA
root procedures total
28
ROSS
50
Bentall Bioprosthetic
12
bentall homograft root replacement
22
Bentall mechanical
31
root sparing (David/YACOUB)
15
root reconstruction
Date range for all data is June 2023-May 2024.
“The success of our advanced aortic program is due to our commitment to offering our community advanced treatment approaches and surgical options, including cutting-edge endovascular aortic, valve-sparing root and Ross procedures while providing the highest-quality outcomes.”
William Brinkman, MD
Medical Director, Thoracic Aortic Surgery Program
Mazin Foteh, MD
Medical Director, Aortic Therapy and Innovation
Innovations
- Developed a strong publication supporting the durability of valve-sparing root replacement (VSRR) in bicuspid and tricuspid aortic valves showing that VSRR can be safely performed on patients with BAV and TAV morphology, yielding similar midterm freedom from mortality, recurrent >2+ AI, and reoperation.
- Spearheading the North American Ross Consortium with three other centers.
- One of fewer than 40 centers in the US to actively participate in the International Registry of Acute Aortic Dissection (IRAD), a consortium of research centers evaluating the current management and outcomes of acute aortic dissection and intramural hematoma.
- Actively enrolling patients in the ARISE II trial, a pivotal clinical trial using minimally invasive stent graft technology to treat the ascending aorta.
Quality awards 2024
Achievements placing us among the elite
Previous
Next